Lysin GN123 Resensitizes Cabapenem-Resistant Pseudomonas aeruginosa to Imipenem Presented at ECCMID 2019, April 13, 2019
Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid against biofilm-forming Staph epidermidis isolates Presented at ECCMID 2019, April 13, 2019
Comparison of Lysin CF-301 (exebacase) Activity Against S. aureus Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates Presented at ID Week 2018, October 5, 2018
CF-301 (Exebacase) Resensitizes Methicillin-Resistant Staphylococcus aureus (MRSA) to Penicillin Derivatives and First Generation Cephalosporins Presented at ASM-ESCMID 2018, September 4, 2018
Bacteriophage Lysins Can Be Engineered to Exert a Rapid and Potent Bactericidal Effect against Pseudomonas aeruginosa in Serum Presented at ASM 2018, June 10, 2018
Lysin CF-301 Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis Presented at ASM 2018, June 10, 2018
Lysin CF-301 Administered in Addition to Vancomycin (VAN) Suppresses the Emergence of Reduced Susceptibilities to VAN Within Cardiac Vegetations in A Rabbit Model of MRSA Infective Endocarditis (IE) Presented at ASM 2018, June 10, 2018
Lysin CF-301 Demonstrates Potent in Vitro Activity against a Range of Staphylococcus and Streptococcus Species Associated with Complicated Bacteremia and Infective Endocarditis in Humans Presented at ASM 2018, June 10, 2018
CF-301 Activity versus Contemporary Staphylococcus aureus Clinical Isolates from US Hospitals Presented at ASM 2018, June 10, 2018
Lysin CF-301 exhibits a low propensity for decreased susceptibility and prevents daptomycin resistance in a rabbit model of Staph aureus infective endocarditis Presented at 28th ECCMID, April 24, 2018
